Overall verdict
Buy
6.9/10
1-year performance
-7.10%
Score breakdown
Down 7.1% over 1 year, 40% of the 52-week range.
Strongest: Valuation 10.0/10. Weakest: Growth 3.8/10.
24 analysts, target +0.3% vs the price.
The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. It operates through two segments: Evernorth Health Services and Cigna Healthcare. The Evernorth Health Services segment includes Pharmacy Benefit Services and Specialty and Care Services, offering pharmacy benefit management, drug claim adjudication, retail pharmacy network administration, benefit design consultation, drug utilization review, drug formulary management, pharmacy benefits, home delivery pharmacy, specialty pharmacy, specialty pharmaceutical distribution, and clinical programs for whole-person health outcomes.
The Cigna Healthcare segment comprises U.S. Healthcare and International Health, delivering comprehensive medical and coordinated solutions such as employer medical plans, individual and family plans, behavioral health, consumer health engagement, dental, pharmacy management, stop-loss insurance, global health care, and local health care solutions, as well as health care benefits for mobile individuals and employees of multinational organizations.
The company offers other operations, including corporate-owned life insurance, reinsurance, and certain run-off and non-strategic businesses. The company distributes its products and services through brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was formerly known as Cigna Corporation and changed its name to The Cigna Group in February 2023. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Sector
Health Care
Industry
Health Care Providers and Services
Primary listing
Nyse
United States
CEO
Robert Peat
Founded
1792
Employees
67 700
Revenue / employee
4.1M USD
Next earnings
October 30, 2026 (estimated)
Institutional holders
- BlackRock, Inc.8.94%
- VANGUARD CAPITAL MANAGEMENT LLC6.59%
- STATE STREET CORP4.84%
- Dodge & Cox4.64%
- MASSACHUSETTS FINANCIAL SERVICES CO /MA/3.98%
- Sanders Capital, LLC3.87%
- FMR LLC3.06%
- GEODE CAPITAL MANAGEMENT, LLC2.39%
- VANGUARD PORTFOLIO MANAGEMENT LLC2.37%
- Other institutions49.59%
- Rest of the register9.74%
1688 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
315.47 USD
52-week low
239.51 USD
1-year performance
-7.10%
Declining
Year-to-date performance
-3.03%
Declining
Drawdown
-14.33%
Mild pullback
Position in the 52-week range
40% of range
Against the world ETF
Over 17 years, from September 2009 to August 2026, the share did not do better than the world ETF once risk is accounted for. It earned more, but shaking 2.1 times harder: for the risk taken, the ETF paid better.
10,000 € placed at the end of September 2009 are worth today
| The Cigna Group | 137 371 € |
| World ETF | 74 620 € |
| S&P 500 | 123 025 € |
| Risk-free placement | 11 288 € |
The risk
- Shaking:the share moves 2.1 times as much as the world ETF.
- Worst fall:-41 % between February 2020 and March 2020. 10,000 € placed at the top fell to 5 891 €. The world ETF, at worst: -34 %. Back to its high in 12 months.
The Cigna Group earned more than the world ETF since 2009
Value of 10,000 euros placed at the end of September 2009, dividends reinvested, in euros
- The Cigna Group: 137 371 €
- World ETF: 74 620 €
- S&P 500: 123 025 €
- Risk-free placement: 11 288 €
Based on past performance. This is not a recommendation.
Range: 526.41 USD - 557.18 USD (2 methods agree)
The price implies growth of -7.62% per year; the company grows at -0.69%.
Gross margin 20.7%, net margin 2.3%, ROIC 9.3%, ROE 15.5%.
Net margin
2.27%
Low
Sector 3.25%|S&P 12.97%
Gross margin
20.66%
Low
Return on equity (ROE)
15.49%
Exceptional
Sector 6.71%|S&P 16.52%
Return on invested capital (ROIC)
9.27%
Exceptional
Free cash flow margin (FCF)
3.23%
Low
Profit-to-cash conversion (FCF conversion)
1.42x
Fair
Margin stability
1.4 pts
Very steady
Revenue to net income
Growth
3.8/10Revenue up 6.5% over 1 year, 11.4% a year over 5, EPS -0.7% a year over 5.
Revenue (trailing 12 months)
282Md USD
Revenue growth (1y)
6.50%
Moderate
Revenue growth (3y)
52.68%
Strong
EPS growth (1y)
10.08%
Moderate
EPS CAGR (5y)
-0.69%
Declining
EPS revisions (3 months)
0.36%
Revised up
Valuation
10.0/10P/E 11.2x, forward P/E 10.8x, EV/EBITDA 7.4x, PEG 0.35. The multiple sits in the 11th percentile of its own 5-year history.
P/E (TTM)
11.2x
Cheap
Sector 30.9x|S&P 23.0x
Forward P/E
10.8x
Cheap
EV / EBITDA
7.4x
Cheap
Sector 12.6x|S&P 14.5x
PEG
0.35
Growth unpriced
Sector 0.23|S&P 0.86
Fair value (reverse DCF)
541.80 USD
Deeply undervalued
P/E vs its own 5-year history
among the 11% lowest valuations
Far cheaper than usual
Market cap
70.9Md USD
Financial strength
5.2/10Cash covers 19.8% of the debt, net debt/EBITDA 1.8x.
Net debt / EBITDA
1.8x
Solid
Gearing (net debt / equity)
59.61%
Solid
Cash
6.3Md USD
Cash / market cap
8.88%
Solid
Cash / total debt
19.76%
Tight
Interest coverage
7.2x
Solid
Net debt
25.6Md USD
Equity
42.9Md USD
Closed daily candles, 2 years
Last close on September 24, 2026: 265.50 USD
- MM20278.78
- MM50280.59
- MM200279.87
- RSI 1435.8
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+0.32%
200-day average slope, 3 months
-0.40%
50-day average slope, 1 month
-1.21%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
1.51 % per day
Volatility change
-12.75%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 24.96 (11) | 30.51 (24) | 286 762 (16) | 13 148 (14) | 6 567 (12) |
| 2027 | 28.28 (11) | 33.44 (24) | 298 543 (16) | 14 137 (14) | 7 525 (12) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of September 24, 2026.
Same sub-industry: 77 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | HNGE | 7.2 | 6.6 | 7.4Md USD | 71.1x | 14.8 % | 53.0 % | 29.3 % | -3.8x | 3.8 % | 55.7 % | ||
| 2 | CI | 6.9 | 7.1 | 70.9Md USD | 11.2x | 2.3 % | 6.5 % | 9.3 % | 1.8x | 12.9 % | -7.1 % | ||
| 3 | LH | 6.7 | 5.9 | 24.7Md USD | 25.1x | 7.0 % | 5.8 % | 6.8 % | 2.4x | 4.7 % | 10.4 % | ||
| 4 | CVS | 6.6 | 5.9 | 110Md USD | 22.7x | 1.2 % | 7.2 % | 3.2 % | 4.1x | 10.7 % | 10.9 % | ||
| 5 | DVA | 6.5 | 6.4 | 11.7Md USD | 15.4x | 5.9 % | 5.2 % | 6.9 % | 4.5x | 13.8 % | 32.3 % | ||
| 6 | DGX | 6.5 | 5.8 | 25.7Md USD | 24.7x | 9.2 % | 10.2 % | 7.9 % | 2.8x | 5.2 % | 26.9 % | ||
| 7 | BTSG | 6.4 | 4.9 | 11.0Md USD | 41.7x | 1.7 % | 23.0 % | 5.7 % | 4.6x | 3.6 % | 102.1 % | ||
| 8 | FME | 5.3 | 6.7 | 12.0Md USD | 11.8x | 4.8 % | 1.4 % | 4.3 % | 2.7x | 17.0 % | -10.0 % | ||
| 9 | GH | 4.7 | 2.6 | 23.7Md USD | Not meaningful (loss) | -38.3 % | 44.3 % | -37.0 % | -1.5x | -1.0 % | 189.0 % |
